Clinical trial
CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.
NCT04226248 is registered in ClinicalTrials.gov with University of Bristol as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.
- Lead sponsor
- University of Bristol
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 2, 2020
- Completion date
- July 24, 2025
- Enrollment
- 600 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.